

This scenario is based on the following projects:

1. Bioassays .....	3.4
2. Additives/materials .....	3.6
3. Technical support to CAC.....	0.3
4. International standards .....	0.2
5. Sidestream formation.....	1.2
6. Specialised analysis.....	0.5
7. Chemical analysis.....	1.0
8. Tar modification .....	2.0
9. "Other noxa" in smoke .....	2.0
10. Technical/Admin support.....	2.7

Supporting notes for the above projects:

1 - 4 are accepted by all CAC's and presumably need no further amplification.

5 Sidestream formation - the work on mechanisms of sidestream formation is key to the future development of low sidestream products and enables BAT to challenge erroneous claims on sidestream composition/hazards.

6 and 7 represent the highly specialised analytical resources needed for the other projects covered in this portfolio eg other noxa.

8 Tar Modification - this work is specifically linked to the evolution of very low tar/normal nicotine product (Greendot). We have already achieved considerable success with a product development (4 mg tar/0.6 mg nic) that emanated from the early research. This work sets the basis for much lower tar/nic ratio products. Commercially the products are important in markets where deliveries are disclosed on the pack but it also meets the interests of various regulatory bodies.

9 "Other noxa" in smoke - this work anticipates the interest of regulatory bodies in specific toxic components (hydrogen-cyanide, acetaldehyde etc). Good progress has been made in 1991 in finding means of reducing many such components by enzymic treatment of tobacco followed by reconstitution.

10 Technical Admin/support - includes the MSD, personnel services and library/info costs associated with these projects.

I believe this scenario to be acceptable as a compromise although, ITL and Souza Cruz may consider it dangerously restricted.

400439784

B.A.T. CONFIDENTIAL - CATEGORY I: MINNESOTA TOBACCO LITIGATION

BATCo document for Province of British Columbia 23 April 1999